MiNK Therapeutics Inc. has announced updated clinical results from a study evaluating its allogeneic invariant natural killer T (allo-iNKT) cell therapy, agenT-797, both as a monotherapy and in combination with anti-PD-1 therapy. The data, presented at the Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting 2025, involved patients with advanced solid tumors that were refractory to all approved treatments, including checkpoint inhibitors. The results demonstrated durable survival, deep and lasting responses, and evidence of immune reactivation, with a reported median overall survival of approximately 23 months when agenT-797 was combined with anti-PD-1 therapy. The therapy showed a favorable safety profile and consistent activity across tumor types, supporting the potential of iNKT cells as a new class of immune-restorative therapy. MiNK Therapeutics plans to advance agenT-797 into Phase 2 studies.